FFA
SRPT icon

Farther Finance Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Farther Finance Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.7K Sell
2,328
-1,590
-41% -$30.1K ﹤0.01% 3389
2026
Q1 		$86.7K Sell
3,918
-2,251
-36% -$43.6K ﹤0.01% 2609
2025
Q4 		$133K Buy
6,169
+6,042
+4,757% +$127K ﹤0.01% 2169
2025
Q3 		$2.45K Buy
127
+22
+21% +$392 ﹤0.01% 4066
2025
Q2 		$1.8K Buy
105
+20
+24% +$853 ﹤0.01% 3737
2025
Q1 		$5.26K Sell
85
-219
-72% -$23.1K ﹤0.01% 3034
2024
Q4 		$37K Buy
304
+2
+0.7% +$245 ﹤0.01% 1806
2024
Q3 		$37.7K Buy
302
+12
+4% +$1.66K ﹤0.01% 1792
2024
Q2 		$45.5K Buy
290
+222
+326% +$28.5K ﹤0.01% 1457
2024
Q1 		$8.73K Buy
68
+3
+5% +$367 ﹤0.01% 1816
2023
Q4 		$6.27K Buy
65
+43
+195% +$4.13K ﹤0.01% 1848
2023
Q3 		$2.67K Buy
22
+3
+16% +$339 ﹤0.01% 1747
2023
Q2 		$2.18K Hold
19
– – ﹤0.01% 1723
2023
Q1 		$2.62K Hold
19
– – ﹤0.01% 1542
2022
Q4 		$2.46K Buy
+19
New +$2.2K ﹤0.01% 1383

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Farther Finance Advisors's SRPT Position: Q2 2026 in Review

Farther Finance Advisors reduced its Sarepta Therapeutics (SRPT) stake by 41% in Q2 2026, selling an estimated $30.1K and leaving 2,328 shares worth $41.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3389.

Farther Finance Advisors first reported a position in SRPT in Q4 2022 and has held it in 15 quarters since. The position peaked at $133K in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Farther Finance Advisors held 2,328 shares of Sarepta Therapeutics worth $41.7K as of Q2 2026.
  • Farther Finance Advisors sold 1,590 Sarepta Therapeutics shares in Q2 2026, an estimated $30.1K.
  • Sarepta Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #3389 holding.
  • Farther Finance Advisors first reported a position in Sarepta Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Farther Finance Advisors's Sarepta Therapeutics position peaked at $133K in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.